🔗 Share this article The Global Health Body Raises Concern Over Critical Lack of Obesity Jabs Less than one in 10 people that would benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it issues its first advice on the therapies. Considering more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication. According to projections, over two billion are projected to be living with obesity by 2030 without intervention. "Our new guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are significant obstacles to widespread access to the treatments that can aid individuals in losing significant weight, says the body. Skinny Jab Scarcity Despite the current best projected scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of the global need, according to the health organization. The recommendation urges governments and firms to widen availability, via approaches including licensing agreements. A patent on semaglutide – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026. How Weight-Loss Injections Work GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so users eat less. Individuals usually see weight reduction within a few weeks of starting on the regular doses. Evidence indicates people may regain a significant portion a year later of discontinuing the medication, because their normal appetite come back. To be above a healthy weight raises your likelihood for experiencing health problems, including type 2 diabetes, heart disease, stroke, and certain malignancies. Excess weight impacts individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.
Less than one in 10 people that would benefit from GLP-1 drugs like Wegovy are able to get them, states the global health agency as it issues its first advice on the therapies. Considering more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication. According to projections, over two billion are projected to be living with obesity by 2030 without intervention. "Our new guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are significant obstacles to widespread access to the treatments that can aid individuals in losing significant weight, says the body. Skinny Jab Scarcity Despite the current best projected scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of the global need, according to the health organization. The recommendation urges governments and firms to widen availability, via approaches including licensing agreements. A patent on semaglutide – the main ingredient of the drug Wegovy – is due to expire in several nations in 2026. How Weight-Loss Injections Work GLP-1 drugs mimick a body's own hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so users eat less. Individuals usually see weight reduction within a few weeks of starting on the regular doses. Evidence indicates people may regain a significant portion a year later of discontinuing the medication, because their normal appetite come back. To be above a healthy weight raises your likelihood for experiencing health problems, including type 2 diabetes, heart disease, stroke, and certain malignancies. Excess weight impacts individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, as per the WHO.